Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non–Small Cell Lung Cancer - Inria - Institut national de recherche en sciences et technologies du numérique Accéder directement au contenu
Article Dans Une Revue JAMA oncology Année : 2020

Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non–Small Cell Lung Cancer

Hugues Talbot

Résumé

Question: Are the different definitions used to assess HPD representative of a same tumoral behaviour? Findings: For this multicentre cohort study including 406 patients with advanced NSCLC treated with PD-1/PD-L1 inhibitors, the different definitions resulted in diverse incidences, patients' characteristics and correlations with survival outcomes. Meaning: The 5 definitions are not representative of a same tumoral behaviour. We defined a new criteria ΔTGR > 100 that looks more accurate assessing HPD.
Fichier principal
Vignette du fichier
Article definitions HPD.pdf (1.04 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03144929 , version 1 (19-02-2021)

Identifiants

Citer

Baptiste Kas, Hugues Talbot, Roberto Ferrara, Colombe Richard, Jean-Philippe Lamarque, et al.. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non–Small Cell Lung Cancer. JAMA oncology, 2020, 6 (7), pp.1039. ⟨10.1001/jamaoncol.2020.1634⟩. ⟨hal-03144929⟩
103 Consultations
204 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More